Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 20, 2026 08:30 ET | Source: Zelluna ASA

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie

Regulatorisk godkjenning muliggjør oppstart av klinisk testing og markerer overgang til klinisk faseFørste kliniske data forventes fra medio 2026 Oslo, Norge, 20 februar 2026 – Zelluna (OSE: ZLNA)...
February 20, 2026 08:30 ET | Source: Zelluna ASA

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 –...
February 12, 2026 01:00 ET | Source: Zelluna ASA

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd med CTA-innlevering

Oslo, 12. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, presenterer i dag...
February 12, 2026 01:00 ET | Source: Zelluna ASA

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission

Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today...
February 11, 2026 02:00 ET | Source: Zelluna ASA

Zelluna inngår avtale med Medpace om første kliniske studie – pasientdata ventes fra medio 2026

Global CRO-partner skal støtte gjennomføring av ZIMA-101 studie med verdens første MAGE-A4-rettede TCR-NK celleterapiproduktAvtalen kommer etter innlevering av søknad om oppstart av klinisk studie...
February 11, 2026 02:00 ET | Source: Zelluna ASA

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial

Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA ...
February 05, 2026 07:30 ET | Source: Zelluna ASA

Zelluna ASA - Grant of Share Options

Oslo, 5 February 2026: On the basis of the authorization granted by the General Meeting on 29 April 2025 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to...
February 05, 2026 03:30 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation

Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a...
February 03, 2026 02:00 ET | Source: Zelluna ASA

Zelluna utnevner Emilie Gauthy til Chief Technology Officer

Oslo, Norge – 3. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, kunngjorde...
February 03, 2026 02:00 ET | Source: Zelluna ASA

Zelluna promotes Emilie Gauthy to Chief Technology Officer

Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers,...